Columbus Regional Health is pleased to offer the OmniaSecure™ defibrillation lead, a novel advancement in transvenous defibrillation lead technology used within an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-Ds).

A lead senses the heartbeat and transmits signals to the implanted device, which then delivers therapy to correct or interrupt abnormally fast rhythms that can result in sudden cardiac arrest (SCA). The OmniaSecure defibrillation lead was developed based on the Medtronic SelectSecure™ Model 3830 pacing lead, which has provided safe and reliable treatment to patients for more than 20 years. [The first procedure at Columbus Regional Hospital was preformed earlier this year by Dr. Albert Sey, interventional cardiologist. 

In 2025, the U.S. Food and Drug Administration (FDA) approved the Medtronic OmniaSecure™ defibrillation lead, which demonstrated safety and efficacy^[i] in patients who are at risk of SCA. The OmniaSecure defibrillation lead improves reliability while maintaining a strong safety profile and is indicated for adults and adolescent pediatric patients ages 12 and up, including those with smaller anatomies.

FDA approval was based on the LEADR Pivotal trial, a global clinical study that assessed the safety and effectiveness of the OmniaSecure defibrillation lead when placed at traditional locations in the right ventricle to achieve defibrillation, sensing, pacing and cardioversion in patients at risk of sudden cardiac death. The global clinical trial found that the OmniaSecure lead showed high defibrillation efficacy, low complications, and reliable performance, exceeding its pre-specified performance threshold.